Bioven (intravenous immunogloblin)
/ Biopharma Plasma
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
September 23, 2024
Intravenous Immunoglobulin (IVIG, Bioven) Efficacy and Safety in Chronic Primary Immune Thrombocytopenia (ITP) in Adults
(clinicaltrials.gov)
- P3 | N=32 | Completed | Sponsor: Biopharma Plasma LLC | Recruiting ➔ Completed
Trial completion • Hematological Disorders • Immune Thrombocytopenic Purpura • Thrombocytopenia • Thrombocytopenic Purpura
June 16, 2022
Intravenous Immunoglobulin (IVIG, Bioven) Efficacy and Safety in Chronic Primary Immune Thrombocytopenia (ITP) in Adults
(clinicaltrials.gov)
- P3 | N=36 | Recruiting | Sponsor: Biopharma Plasma LLC
New P3 trial • Hematological Disorders • Thrombocytopenia • Thrombocytopenic Purpura
October 14, 2020
Intravenous Immunoglobulin (IVIG, Bioven) Efficacy Assess for COVID-19 / SARS-CoV-2 Severe Pneumonia Complex Treatment
(clinicaltrials.gov)
- P3; N=76; Completed; Sponsor: Biopharma Plasma LLC; Recruiting ➔ Completed
Clinical • Trial completion • Immune Modulation • Infectious Disease • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases • CRP • IL6
August 07, 2020
Intravenous Immunoglobulin (IVIG, Bioven) Efficacy Assess for COVID-19 / SARS-CoV-2 Severe Pneumonia Complex Treatment
(clinicaltrials.gov)
- P3; N=76; Recruiting; Sponsor: Biopharma Plasma LLC
Clinical • New P3 trial • Hemophilia • Immune Modulation • Infectious Disease • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases • CRP • IL6
1 to 4
Of
4
Go to page
1